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In one third of Finnish patients with the heterozygous form of familial hypercholesterolemia the disease is due to a gross 
deletion at the 3’-end of the LDL receptor gene. The present study demonstrates that an 8-kb deletion completely elimi- 
nates exons 16 and 17 and a part of exon 18. Cloning and partial sequencing of a DNA fragment from the mutated 
allele indicated that the S-boundary of the deletion lies within intron 15 while the 3’-breakpoint is located at nucleotide 
3390 in exon 18. RNA blot hybridization studies revealed that the mutated allele encodes a truncated 4.2 kb mRNA 
(normal, 5.3 kb). This type of mutation has not been reported in other ethnic groups. 
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1. INTRODUCTION 
Familial hypercholesterolemia (FH) is a disease 
where a defect in the low density lipoprotein (LDL) 
receptor gene impairs cholesterol homeostasis 
leading to increased concentration of plasma LDL 
and premature atherosclerosis [I]. Patients that are 
heterozygous for a mutated receptor gene have 
serum LDL cholesterol evels approximately twice 
as high as normal and suffer, if untreated, from 
myocardial infarction typically at the age of 40 to 
50 years [2]. About 1 in every 500 people carries 
one mutated allele and one normal gene [3]. The 
homozygous form of the disease is extremely rare. 
These patients may have serum LDL cholesterol 
levels up to six times normal and many of them 
succumb to ischemic heart disease in childhood [ 11. 
The human LDL receptor is a transmembrane 
glycoprotein comprising 839 amino acids [4]. The 
receptor gene extends 45 kb and consists of 18 ex- 
ons and 17 introns [l]. Exon 1 encodes the 
hydrophobic signal peptide, and exons 2-16 en- 
code the extracellular, including ligand-binding, 
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areas of the receptor. Portions of exons 16 and 17 
encode the membrane spanning region of the 
receptor, while the 3’-part of exon 17 and the 
5 ‘-part of exon 18 encode the cytoplasmic 
carboxy-terminal tail of the receptor [5]. 
So far about 17 different mutations of the LDL 
receptor gene have been characterized [ 1,6- 181. 
Some mutations apparently disrupt the biosyn- 
thesis or the transport of the receptor from en- 
doplasmic reticulum to Golgi complex, while some 
affect the binding of LDL to the receptor or the 
clustering of the receptor-LDL complexes in 
coated pits. The spectrum of LDL receptor gene 
mutations in a given population may be narrower, 
the more homogeneous the population is in genetic 
terms. We found recently that one type of muta- 
tion of the LDL receptor gene affects about one- 
third of Finnish FH patients [ 181. This paper 
describes the molecular-characteristics of
tant gene and the corresponding mRNA. 
the mu- 
2. MATERIALS AND METHODS 
2.1. Cloning of the deletion point 
Total genomic DNA was prepared [19] from blood 
leukocytes of a heterozygous FH patient (FH-10) carrying the 
Finnish allele of the mutant LDL receptor gene [18]. DNA 
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(3Opg) was digested with the restriction enzyme NcoI (Boeh- 
ringer Mannheim, FRG) and fractionated by gel electrophoresis 
on 0.6% agarose. Fractions in the molecular size range of 2 to 
4 kb were eluted from the gel using a commercial kit 
(GenecIeanTM, La Jolla, USA). The recessed ends created by 
NcoI were filled in by Klenow and EcoRI linkers were added by 
incubating with T., DNA ligase [20]. DNA was then ligated with 
EcoRI cleaved, dephosphorylated hgt 10 arms. The ligated 
DNA was packaged into h phage particles and plated using E. 
co/i Y 1090 cells. The library (lo6 recombinants) was screened 
using an LDL receptor cDNA probe covering exons lo-17 [18]. 
One positive clone was found. The inserted DNA was excised 
by EcoRI digestion, isolated by agarose gel electrophoresis, 
subcloned into the EcoRl restriction site of the plasmid 
pBR322, and used for DNA sequencing and Southern blot 
analysis. This plasmid was designated pFH-Nco. 
2.2. DNA sequencing 
To determine the nucleotide sequence at the 3 ‘-boundary of 
the deletion the following strategies were used: (i) the cloned 
mutated fragment was sequenced starting from its 3 ‘-end using 
a 16 nucleotide pBR322 primer (5’-GCAATTTAACTGTGAT- 
3’) close to its EcoRI cloning site; (ii) plasmid pFH-Nco was 
digested with BamHI and religated. This new modified plasmid 
missing a 926 bp BamHl fragment, consisting of a 551 bp 
BarnHI-NcoI fragment of LDL receptor cDNA [4,18] and a 
375 bp EcoRI-BumHI fragment of pBR322 [21], was se- 
quenced from its 3’-end using another 16 nucleotide pBR322 
primer (5 ’ -ATGCGTCCGGCGTAGA-3 ’ ) close to its BamHl 
restriction site. (iii) The complementary strand was sequenced 
using a 17 nucleotide primer (5’-ACCTTCTCTCACTTGGG- 
3’) about 200 bp upstream from the BumHI site in exon 18 of 
the mutant LDL receptor gene. Sequencing was carried out us- 
ing a commercial kit (Sequenase, Cleveland, USA) and about 
400 nucleotides were sequenced at a time. The sequence was 
compared to that of exon 18 of the normal LDL receptor gene 
]41’ 
2.3. Southern blot analysis 
The plasmid pFH-Nco (see above) was digested with EcoRI 
overnight at 37°C. A plasmid containing the normal LDL 
receptor cDNA sequence (pLDLR3, kindly provided by Dr 
D.W. Russell, see [4]) was used as a positive control. This 
cDNA was first cleaved with XhoI to eliminate exon 18 contain- 
ing a cluster of Alu sequences [4], and then religated. This 
plasmid containing almost the entire protein coding sequence of 
the LDL receptor gene, missing only the last 36 coding 
nucleotides, was then digested with XhoI and BarnHI. DNA 
fragments were fractionated by electrophoresis on 0.6% 
agarose, denatured, neutralized and transferred to nitrocel- 
lulose filter. The filters were hybridized in a solution containing 
0.9 M NaCl, 0.09 M Tris-HCl, pH 7.6, 1 mM EDTA, 0.5% 
sodium lauroylsarcosine, 0.1 mg/ml tRNA, 1 x Denhardt’s 
solution and a synthetic 17-mer oligonucleotide probe, either 
specific for exon 15 (5 ’ -GACAATGTCTCACCAAG-3 ‘) or 
exon 16 (5 ’ -TCCATTGTCCTCCCCAT-3 ‘) [4,5]. Labelling of 
the oligonucleotide probes was accomplished using T4 poly- 
nucleotide kinase [20]. After hybridization for 16 hat 42”C, the 
filters were washed with 2 x SSC (1 x SSC: 0.15 M NaCl, 
0.015 M trisodium citrate), 0.1% SDS at 22°C and with 0.2 x 
SSC, 0.1% SDS at 42°C. Autoradiography of the dried filters 
was conducted by exposing them to Kodak XAR films for 
3-8 h at -70°C. 
2.4. mRNA analysis 
An incisional skin biopsy was taken from the forearm of the 
patient FH-10 and fibroblasts were grown using standard cell 
culture techniques. HepG2 (a human hepatoma cell line) cells 
were obtained from American Type Culture Collection 
(Rockville, USA). Total RNA from approx. l-2 x 10’ cells was 
,._--__-- ______ --probe_---_--__-, 
10 1112 1314 15 16 17 18 
1 kb 
Fig.1. (A) An autoradiogram of NcoI-digested DNA samples from a FH-patient (FH-10, lane 1) and a control subject (lane 2) 
hybridized with a 3zP-labelled LDL receptor probe. The abnormal fragment of the patient’s DNA is shown by an asterisk. (B) NcoI 
(N) restriction map of the 3’-end of the LDL receptor gene (data from [19,28]). Also shown are the 5’- and 3’-boundaries of the cDNA 
probe used in Southern blotting (A). The asterisk indicates the abnormal 3 kb NcoI fragment that was generated from the mutant 
allele and subsequently cloned. 
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isolated by the LiCl-urea method [22] and enriched in poly(A)- 
containing RNA by oligo(dT)-cellulose affinity chro- 
matography [23]. RNA samples (2pg) were fractionated on 
0.6% agarose gels containing 2.2 M formaldehyde [20] and 
transferred to nitrocellulose filters. Hybridization of the filter- 
bound RNA was carried out in a solution containing 6 x SSC, 
0.1% SDS, 5 x Denhardt’s solution, lOOpg/ml herring sperm 
DNA, 50% deionized formamide, and l-2 x lo6 cpm/ml of 
32P-labelled (Multiprime DNA labelling system, Amersham, 
Buckinghamshire, England) LDL receptor cDNA probe. The 
probe was a modified version of the plasmid pLDLR3 [4] con- 
taining the nucleotides from 1573 to 2544 of the receptor 
cDNA. After hybridization for 20 h at 42°C the filters were 
washed with 2 x SSC, 0.1% SDS at 22°C and with 0.2 x SSC, 
0.1% SDS at 42”C, and exposed to Kodak XAR films for l-3 
days at -70°C. 
3. RESULTS 
Our earlier studies demonstrated that about 
30% of the Finnish FH patients carry a similar 
type of deleted LDL receptor gene [ 181. In order to 
precisely define the mutation, a portion of the ab- 
normal gene was isolated from a genomic DNA 
library derived from an FH patient known to carry 
the deleted allele. Restriction mapping of the 
deleted gene [ 181 indicated that a partial genomic 
library prepared by digestion with the enzyme 
NcoI and enriched for fragments with a molecular 
size of about 3 kb would contain the deletion point 
(fig. 1). 
The cloned NcoI fragment was partially se- 
quenced using primers of plasmid pBR322. Start- 
ing from its 3’-end, the upstream sequence was 
found to be identical with the normal exon 18 se- 
quence up to nucleotide 3390 and to be entirely dif- 
ferent beyond that site (fig.2). 
In order to determine the 5 ‘-boundary of the 
deletion, plasmids containing the normal LDL 
receptor coding sequence and the cloned NcoI 
fragment from the patient FH-10 were analyzed by 
Southern blotting using exon 15 and exon 16 
specific oligonucleotide probes. The normal cDNA 
sequence hybridized with both oligonucleotide 
probes, whereas the cloned DNA fragment from 
the patient hybridized only with the exon 15 
specific probe (fig.3). 
RNA blot hybridization analysis of poly(A)- 
containing RNA from a human hepatoma cell line 
(HepG2) known to express LDL receptors 124,251, 
and fibroblasts of a normal subject revealed a 
A. 
A CGT 
FH-10 N 
3380 
B. 
15 18 
Fig.2. (A) Autoradiogram of a sequencing gel demonstrating 
the mutation point at exon 18 of the patient FH-10. The DNA 
sequences of the non-coding and coding strands of the mutant 
allele as well as the coding strand of the normal allele are 
shown. Matching DNA sequences are indicated by horizontal 
bars. Numbering refers to the normal nucleotide sequence of 
the LDL receptor cDNA [4]. (B) Sequencing strategy for the 
mutant gene. The arrows show direction and extent of each 
sequence determination. For detail, see section 2. 
single 5.3 kb mRNA species (fig.4). RNA from the 
heterozygous patient FH-10 contained two 
hybridizable mRNA species, one with an apparent- 
ly normal size and another smaller but more inten- 
sive one with a size of about 4.2 kb (fig.4). 
413 
Volume 234, number 2 FEBS LETTERS July 1988 
A m 
123 45  
Bi  
1 2 3 
C|  
1 2 3 
m 
m 
m 
m 
m 
m 
kb  
23.1 
9.4 
6.6 
4.3 
2.3 
2.0 
1.6 
0.5 
!! i / i  i ~ iii! !i~/? iii' ~ ,iii 
Fig.3. (A) Agarose gel electrophoresis of plasmids containing mutant and normal LDL receptor gene sequences (stained with ethidium 
bromide). Lanes: 1 and 2, EcoRI digested plasmid pFH-Nco (run in duplicate); 3, a plasmid containing a normal LDL receptor cDNA 
sequence, digested with XhoI and BamHI; 4 and 5, HindIlI-digested A-DNA and Hinfl-digested pBR322, respectively, run as 
molecular size markers. (B and C) Southern blot analysis of nitrocellulose-transferred DNA fragments shown in (A), hybridized with 
an exon 15 specific oligonucleotide probe (B), or an exon 16 specific oligonucleotide probe (C). Lanes: 1 and 2, EcoRI-digested plasmid 
pFH-Nco (run in duplicate); 3, a plasmid containing a normal LDL receptor cDNA sequence digested with Xhol and BamHI. 
4. D ISCUSSION 
We have previously shown that about one third 
of  Finnish patients with FH have an LDL receptor 
gene defect which is due to a large deletion at the 
3 ' -end of  the structural gene [18]. By direct DNA 
sequencing, the present study demonstrates that 
the 3 ' -breakpoint  of  the mutat ion lies at exon 18 
deleting the 5 ' -end of  this exon up to base pair 
3390 and retaining the 3 ' -end of  the exon from 
base pair 3391 (for nucleotide positions see [4]). 
The exact boundary of  the deletion at its 5 ' -end 
cannot be determined. There is circumstantial 
evidence, however, that the recombination occurs 
within intron 15. Firstly, the restriction mapping 
data strongly suggest that this is the case [18]. 
Secondly, the mutant gene does not hybridize with 
an exon 16 specific oligonucleotide probe (fig.3). 
Thirdly, the mutant gene does hybridize with an 
oligonucleotide probe complementary to a DNA 
sequence at the very 3 ' -end of  exon 15 (fig.3). 
Fourthly, the size of  the mRNA generated by the 
mutant gene 1s in excellent agreement with the sug- 
gestion that exon 16 (78 base pairs), exon 17 (158 
base pairs) and a portion from the 5 ' -end of  exon 
18 (deleted area, 843 base pairs) [5] are deleted. 
Apparently, a new acceptor site for splicing is 
formed in exon 18, located 3' f rom the mutation 
point; the exact point of  splicing is, however, not 
known. 
Gross deletions of  the LDL receptor gene 
probably represent only 3-6°7o of  the spectrum of 
mutations [16]. Most of  the mutations in the LDL 
receptor gene so far described contain Alu se- 
quence recombinations [6,9-11,13,14]. Alu se- 
quences are present both in exon 18 and intron 15 
[13]. The present data exclude the possibility that 
the Finnish type of mutat ion represents an Alu-Alu 
recombination, the type of  mutation found in FH 
patients f rom the USA [6] and from Japan [13], 
since the deletion point in exon 18 is not localized 
in the Alu region, nucleotides 3704-4465 [4]. This 
study and another recently published report [17] 
are in accordance with the assumption of  Lehrman 
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Fig.4. Northern blot hybridization analysis of poly(A)- 
containing RNA from a human hepatoma cell line, HepG2 
(lane l), fibroblasts of a healthy control subject (lane 2) and a 
patient with FH (FH-IO, lane 3). 
et al. [13] that there is some intrinsic instability in 
intron 15. 
Several types of deletions at the 3 ’ -end of the 
LDL receptor gene have been described in dif- 
ferent ethnic groups, including American [6,9], 
Caucasian [ 1 l] and Japanese [ 13,171 populations. 
None of them, however, appear to be identical 
with the Finnish one described in the present 
paper. Although the exact structure of the receptor 
encoded by the Finnish type of mutation remains 
to be investigated, it may be expected to have 
grossly altered transmembrane and cytoplasmic 
domains or to be entirely devoid of them. Thus, it 
is very likely that the Finnish type of mutant allele 
encodes, like other mutant genes with defects in 
the same region [6,13], a receptor which displays 
defective internalization of its bound LDL-ligand. 
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